周一盘前，生物制药公司MoonLake Immunotherapeutics（MLTX）股价暴跌86.24%，引起市场广泛关注。这一罕见的大幅下跌主要源于两个重要因素。
首先，加拿大皇家银行（RBC）大幅下调了对MLTX的评级和目标价。RBC将MLTX的投资评级从"跑赢大盘"下调至"板块表现"，同时将目标价从67美元大幅下调至10美元，降幅高达85%。这一举动严重打击了投资者信心，导致股价大幅下挫。
其次，公司最新发布的临床试验结果令人失望。MLTX公布了其Vela三期临床项目的第16周试验结果，该项目正在评估纳米抗体Sonelokimab在治疗化脓性汗腺炎（HS）方面的疗效。虽然具体数据尚未公开，但市场反应表明，这些结果可能未能达到预期，进一步加剧了投资者的担忧。这两个因素叠加，导致MLTX股价在盘前交易中遭遇近乎腰斩的暴跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.